Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of Natera’s ...

Please provide your email address to receive an email when new articles are posted on . Cell-free fetal antigen analyses had 100% consistency for 465 calls on antigens in which women were ...

Dear Dr. Roach: I am 85 and healthy apart from polycythemia vera, for which I take aspirin. I was interested in the new blood test for cancer. Is it worthwhile? Dear M.N.: When screening patients for ...

DEAR DR. ROACH: I am 85 and healthy apart from polycythemia vera, for which I take aspirin. I was interested in the new blood test for cancer. Is it worthwhile? -- M.N. ANSWER: When screening patients ...

A noninvasive blood test to detect genetic material shed by tumors may help clinicians identify adverse events related to treatment with immune checkpoint inhibitor drugs, investigators at the Johns ...

Small cell lung cancer (SCLC) remains a challenging cancer type to treat effectively. While patients initially respond to chemotherapy and immunotherapies, the disease almost always returns, often ...

Please provide your email address to receive an email when new articles are posted on . Biopsies with high donor-derived cell-free DNA levels were likely to reveal antibody-mediated rejection.

A blood test that uses artificial intelligence (AI) to detect cancer-related genetic changes and protein biomarkers could help screen women for early signs of ovarian cancer, according to a new study.

These MRI images with arrows indicating cancer were made during a study by researchers at the National Institutes of Health and published Wednesday, Dec. 4, 2024, in the New England Journal of ...

Dear Dr. Roach: I am 85 and healthy apart from polycythemia vera, for which I take aspirin. I was interested in the new blood test for cancer. Is it worthwhile? — M.N. Answer: When screening patients ...